Summary

Health across the world continues to show major contrasts. Infectious diseases primarily affect countries of the South. Outside of Africa, people are more affected by non-communicable diseases, most of them related to lifestyle and our increasing lifespan. Access to healthcare is a major factor of discrimination in places where there is no universal healthcare and due to the investment and pricing decisions of world pharmaceutical companies.

In the Neolithic Age, when agriculture and husbandry brought people into sustained contact with animals, there were many epidemics. The rise of long-distance trade by land and sea around 1000 CE promoted the globalization of pathogens in Eurasia, and transatlantic voyages subsequently contaminated the Americas and Oceania in the late fifteenth century. From the sixteenth to the nineteenth centuries, most countries adopted a system of quarantine or cordons sanitaires to avoid the spread of infectious diseases (plague, flu, measles, yellow fever, syphilis, cholera, tuberculosis, leprosy, etc.).

Is another epidemic on the way?

The late 19 th century saw the foundation of international organizations to coordinate the fight against epidemics. Into the 1970s, medical advances offered the hope that epidemics could be eradicated through vaccination and the discovery of new treatments. Since that time, the identification of new pathologies (AIDS, SARS [Severe Acute Respiratory Syndrome], bird flu), the rise of certain diseases (dengue, chikungunya, meningitis) and the re-emergence of diseases supposedly eradicated (tuberculosis, smallpox, plague) suggest the possibility of a new outbreak fostered by globalization, climate change, the risk of bioterrorism and inadequate food security.

Infectious diseases primarily affect countries of the South (accounting for 56 % of mortality in Africa, 5 % in Europe). Topping the list of global parasitic diseases is malaria, which affects 216 million people a year and causes 445,000 deaths, 91 % of them in Africa. The failure of attempts at eradication by spraying with insecticide, causing agricultural devastation and the development of resistance in mosquitoes, led to the development of effective drug treatments, but these remain too expensive for most sufferers.

Main causes of death by income level, 2015

Source: WHO, Global Health Observatory, www.who.int/gho

Comment: The table reveals the links between the main causes of mortality and the average level of income per inhabitant in 2015. The populations of high-income countries are more liable to die from non-communicable diseases (neurological causes and cancer in particular) while in low-income countries, people die from infectious diseases (tuberculosis, diarrhea, HIV/aids) or malnutrition. This reverse gradient is less marked in the case of diabetes (due to there being two types) and heart disease.

Non-communicable diseases on the rise

Outside Africa, more people are killed by non-communicable diseases, and this trend is growing. It is thought that in 2030 three-quarters of deaths will be caused by cancer, diabetes, cardiovascular, bronco-pulmonary and neurodegenerative diseases, obesity, mental illness, musculoskeletal problems and road traffic accidents. Most of the diseases listed are linked to lifestyle (diet, alcohol consumption, smoking, sedentary lives, etc.) and the fact that people are living longer.

Diabetes is widespread in rich countries, particularly among the poor, and is now spreading to poorer countries subject to food shortages and nutritional imbalances. In cities, traditional foods face competition from pre-prepared dishes that are higher in fat and sugar. In a sign that a pandemic is on the way, the number of diabetics in the world has multiplied by four in under 40 years, from 108 million in 1980 to 422 million in 2014.

The rate of smoking, which is responsible for 10 % of adult mortality (7 million deaths per year), is stagnating and indeed falling in rich countries, due to prevention, taxation and prosecution of the tobacco industry. Conversely, the rate of direct and indirect smoking is rising in emerging countries and developing countries, promoted by aggressive marketing by cigarette companies; 80 % of today’s 1.1 billion smokers live in low or intermediate income countries, where smoking is growing among women and the young.

Death by non-communicable disease, 2015 

Source: WHO, Global Health Observatory, www.who.int/gho

Comment: The world distribution of death by non-communicable disease shows marked contrasts. The countries with very ageing populations are more susceptible to neurodegenerative illnesses. Those suffering from a combination of unbalanced diets, high alcohol and tobacco consumption, sedentary lifestyles, and exposure to pollution are more affected by cardiovascular diseases and cancer. Mortality from diabetes now impacts the whole world, starting with the poorest.

What price medical care?

The evolution of diseases and global increases in heath spending have stimulated the global pharmaceutical industry. However, the large multinational companies based in developed countries show little concern for the needs of developing and emerging countries: less than 10 % of investment in medical research goes to the so-called neglected diseases that account for 90 % of global morbidity (leishmaniasis, leprosy, Chagas disease, sleeping sickness, malaria, etc.).

Yet diseases such as hepatitis C––chronically carried by 71 million people and killing nearly 400,000 a year––could be eradicated. New antiviral drugs provide an effective cure in over 95 % of infected individuals. In the absence of universal healthcare, access to costly diagnosis and treatment remains beyond the reach of disadvantaged populations, who are also the most likely to be affected by an epidemic, due to the modes of contamination. Vulnerable populations are also more likely to fall prey to the boom in counterfeit drugs (10 % of the global market, rising to 30 % in developing and emerging countries), the controversial practices of some pharmaceutical companies (testing new drugs before market authorization) and environmental effects (pollution of waste water by the active ingredients of drugs).

The World’s 20 Leading Pharmaceutical Companies, 2016

Source: www.pharmexec.com/pharm-execs-top-50-companies-201 7

Comment: These data, produced by the pharmaceutical industry itself, show the influence of the large multinationals in the sector (10 American and 8 European among the top 20, adding up to almost 500 billion dollars of revenue), the contribution of their flagship medicines to their total revenue and the type of pathologies they treat (cancer: 8.8% of revenue, diabetes: 5%).

Contrasts and InequalitiesGender and SexualityContrasts and InequalitiesCompetition for Knowledgeback to top